Epitope mapping of PfCP-2.9, an asexual blood-stage vaccine candidate of Plasmodium falciparum

Malaria Journal

Table 3 General description of the substitutions made within PfCP-2.9

Designationa	Location on PfCP-2.9	Positionb	Amino acid		Selection	Reference
Designationa			PfCP-2.9	Mutant	Selection	Reference
M17	AMA-1(III)	446	Tyr	Phe	c	[24]
M18	AMA-1(III)	447	Lys	Arg	c	[24]
M55	AMA-1(III)	484	Asp	Asn	c	[24]
M56	AMA-1(III)	485	Lys	Arg	d	[25]
M62	AMA-1(III)	491	Phe	Ala	d	[25]
M71	AMA-1(III)	500	Ser	Thr	c	[24]
M81	AMA-1(III)	510	Val	Ile	d	[25]
M82	AMA-1(III)	511	Glu	Gln	c	[24]
M84	AMA-1(III)	513	Arg	Lys	c	[24]
M159	MSP1-19	14	Gln	Gly	e	[19]
M160	MSP1-19	15	Asn	Arg	f	[13]
M165	MSP1-19	20	Arg	Glu	e	[19]
M172	MSP1-19	27	Glu	Tyr	f	[13]
M174	MSP1-19	29	Lys	Arg	e	[19]
M176	MSP1-19	31	Leu	Arg	f	[13]
M185	MSP1-19	40	Lys	Ile	e	[19]
M188	MSP1-19	43	Glu	Leu	f	[13]

a. Mutated proteins are designated with the corresponding sequence number of the amino acid residues on PfCP-2.9
b. Positions for the substitutions numbered from the start of PfAMA-1 (3D7 line) or of PfMSP1-19 (Wellcome/K1 line).
c. Highly conserved amino acids across different Plasmodium species.
d. Epitopes recognized by mAbF8.12.19.
e. Surface-exposed amino acids on the PfMSP1-19 molecule.
f. Epitopes recognized by blocking mAbs.

ISSN: 1475-2875